BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Verstovsek, S; Al-Ali, HK; Mascarenhas, J; Perkins, A; Vannucchi, AM; Mohan, SR; Scott, BL; Woszczyk, D; Koschmieder, S; Garcia-Delgado, R; Laszlo, R; McGreivy, JS; Rothbaum, WP; Kiladjian, JJ – 2022